RESUMEN
In this selective overview of articles, we describe new concepts, therapeutic measures and pharmacological agents that may modify current practice in clinical internal medicine. Novelties for the management of cardiovascular disease, such as heart failure, hypoxemic respiratory failure, nosocomial pneumonia and certain allergies are discussed.
À travers quelques articles et études choisis, cet article décrit de nouveaux concepts, mesures thérapeutiques et agents pharmacologiques pouvant modifier les pratiques courantes en médecine interne. Des notions concernant la gestion de maladies cardiovasculaires telles que l'insuffisance cardiaque, les décompensations respiratoires hypoxémiques, les pneumonies nosocomiales et la gestion d'allergies y figurent au premier plan.
Asunto(s)
Enfermedades Cardiovasculares , Medicina Clínica , Neumonía Asociada a la Atención Médica , Humanos , Hospitales , Medicina InternaRESUMEN
Acute heart failure is a leading cause of hospitalisations with an increasing economic and public health burden. Management of acute heart failure involves the use of diuretics to treat congestion and improve morbimortality. Despite current guidelines, numerous patients maintain congestion and often leave the hospital setting with incomplete volume depletion, leading to an increased risk of rehospitalisation. A recent multicentric randomised controlled trial studied the administration of acetazolamide in addition to standard care with loop diuretics in the acute setting. There was a significantly faster decongestion, based on a pragmatic clinical score, with very few side effects.
L'insuffisance cardiaque est la première cause d'hospitalisation dans les pays occidentaux, engendrant un coût médico-économique important. La prise en charge médicamenteuse de l'insuffisance cardiaque aiguë comprend l'administration de diurétiques afin de traiter la congestion et d'améliorer la morbimortalité. Toutefois, de nombreux patients présentent encore une congestion importante après plusieurs jours de traitement diurétique et rentrent à domicile avec une congestion résiduelle, augmentant le risque de récidive de décompensation cardiaque et par conséquent de ré-hospitalisation. Dans une étude randomisée multicentrique en double-aveugle, l'acétazolamide utilisé en adjonction d'un traitement diurétique de l'anse a permis une décongestion significativement plus rapide et efficace sans augmentation notable des effets indésirables.
Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Insuficiencia Cardíaca , Humanos , Acetazolamida , Diuréticos/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológico , HospitalizaciónRESUMEN
Hospital based internal medicine has been strongly solicited for over two years with the SARS-CoV-2 epidemic. This epidemic continues to evolve and represents a strain for public health. Numerous studies have addressed issues concerning this epidemic, and multiple novelties concerning other frequent pathologies have also been published. Management strategies of cardiovascular, pulmonary, gastro-intestinal and metabolic diseases are discussed.
La médecine interne hospitalière a été fortement sollicitée depuis 2 ans avec l'épidémie de SARS-CoV-2. Celle-ci continue d'évoluer et reste une épreuve pour la santé publique. Une pléthore d'études a tenté de résoudre les multiples défis que représente cette épidémie, mais de multiples nouveautés concernant d'autres pathologies fréquentes sont également apparues. La prise en charge des maladies cardiovasculaires, pulmonaires, gastro-intestinales et métaboliques est évoquée.
Asunto(s)
COVID-19 , Epidemias , Humanos , SARS-CoV-2 , COVID-19/epidemiología , Hospitales , Medicina InternaRESUMEN
BACKGROUND: Residual kidney function is considered better preserved with incremental haemodialysis (I-HD) or peritoneal dialysis (PD) as compared with conventional thrice-weekly HD (TW-HD) and is associated with improved survival. We aimed to describe outcomes of patients initiating dialysis with I-HD, TW-HD or PD. METHODS: We conducted a retrospective analysis of a prospectively assembled cohort in a single university centre including all adults initiating dialysis from January 2013 to December 2020. Primary and secondary endpoints were overall survival and hospitalization days at 1 year, respectively. RESULTS: We included 313 patients with 234 starting on HD (166 TW-HD and 68 I-HD) and 79 on PD. At the end of the study, 10 were still on I-HD while 45 transitioned to TW-HD after a mean duration of 9.8 ± 9.1 months. Patients who stayed on I-HD were less frequently diabetics (P = .007). Mean follow-up was 33.1 ± 30.8 months during which 124 (39.6%) patients died. Compared with patients on TW-HD, those on I-HD had improved survival (hazard ratio 0.49, 95% confidence interval 0.26-0.93, P = .029), while those on PD had similar survival. Initial kidney replacement therapy modality was not significantly associated with hospitalization days at 1 year. CONCLUSIONS: I-HD is suitable for selected patients starting dialysis and can be maintained for a significant amount of time before transition to TW-HD, with diabetes being a risk factor. Although hospitalization days at 1 year are similar, initiation with I-HD is associated with improved survival as compared with TW-HD or PD. Results of randomized controlled trials are awaited prior to large-scale implementation of I-HD programmes.
Asunto(s)
Fallo Renal Crónico , Diálisis Peritoneal , Adulto , Humanos , Diálisis Renal/métodos , Estudios Retrospectivos , Terapia de Reemplazo RenalRESUMEN
BACKGROUND: Atypical pathogens (AP), present in some patients with community-acquired pneumonia (CAP), are intrinsically resistant to betalactam drugs, the mainstay of empirical antibiotic treatment. Adding antibiotic coverage for AP increases the risk of adverse effects and antimicrobial selection pressure, while withholding such coverage may worsen the prognosis if an AP is causative. A clinical model predicting the presence of AP would allow targeting atypical coverage for patients most likely to benefit. METHODS: This is a secondary analysis of a multicentric randomized controlled trial that included 580 adults patients hospitalized for CAP. A predictive score was built using independent predictive factors for AP identified through multivariate analysis. Accuracy of the score was assessed using area under the receiver operating curve (AUROC), sensitivity, and specificity. RESULTS: Prevalence of AP was 5.3%. Age < 75 years (OR 2.7, 95% CI 1.2-6.2), heart failure (OR 2.6, 95% CI 1.1-6.1), absence of chest pain (OR 3.0, 95% CI 1.1-8.2), natremia < 135 mmol/L (OR 3.0, 95% CI 1.4-6.6) and contracting the disease in autumn (OR 2.7, 95% CI 1.3-5.9) were independently associated with AP. A predictive score using these factors had an AUROC of 0.78 (95% CI 0.71-0.85). A score of 0 or 1 (present in 33% of patients) had 100% sensitivity and 35% specificity. CONCLUSION: Use of a score built on easily obtained clinical and laboratory data would allow safe withholding of atypical antibiotic coverage in a significant number of patients, with an expected positive impact on bacterial resistance and drug adverse effects. TRIAL REGISTRATION: NCT00818610.
Asunto(s)
Infecciones Comunitarias Adquiridas , Neumonía , Adulto , Anciano , Antibacterianos/efectos adversos , Profilaxis Antibiótica , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones Comunitarias Adquiridas/epidemiología , Infecciones Comunitarias Adquiridas/microbiología , Humanos , Neumonía/tratamiento farmacológico , Neumonía/epidemiología , Neumonía/microbiología , beta-Lactamas/uso terapéuticoRESUMEN
Loop diuretics are strongly recommended by current guidelines for the treatment of acute heart failure. Intravenous furosemide can be administered either as a continuous infusion or as an intermittent bolus. The choice between these two routes is not always obvious in clinical practice. The understanding of their different mechanisms of action, as well as the notion of diuretic resistance, can help identify patients who may benefit from either of these two routes. This article aims at discussing these aspects and their pathophysiology, as well as summarizing the current body of evidence from randomized trials comparing continuous vs. intermittent administration of furosemide in acute heart failure.
Les diurétiques de l'anse sont fortement recommandés par les directives cliniques actuelles dans l'insuffisance cardiaque aiguë. Le furosémide intraveineux peut être administré sous formes continue et intermittente. En pratique clinique, le choix de la modalité d'administration n'est pas toujours évident. La compréhension de leur action et des mécanismes de résistance aux diurétiques permet d'identifier les situations cliniques qui répondent le mieux à l'une ou l'autre de ces méthodes d'administration. Cet article a pour but de discuter de ces différents aspects, notamment des mécanismes physiopathologiques en jeu, puis de synthétiser et évaluer le corpus d'évidences randomisées comparant ces deux modalités pour le traitement de l'insuffisance cardiaque aiguë.
Asunto(s)
Furosemida , Insuficiencia Cardíaca , Humanos , Furosemida/uso terapéutico , Inyecciones Intravenosas , Infusiones Intravenosas , Inhibidores del Simportador de Cloruro Sódico y Cloruro Potásico/uso terapéutico , Diuréticos/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológicoRESUMEN
Internal medicine continues de evolve as a result of further insight and evidence for the efficacy of given interventions. Although numerous studies have addressed issues concerning the SARS-COV-2 epidemic, multiple novelties concerning other frequent pathologies have also been presented. Management strategies of cardiovascular disease, infectious diseases and venous thromboembolism are particularly concerned.
La médecine interne continue d'évoluer au fur et à mesure de nouvelles évidences d'efficacité par rapport aux diverses interventions. Une pléthore d'études a tenté de résoudre les multiples défis que représente l'épidémie au SARS-CoV-2, mais de multiples nouveautés concernant d'autres pathologies fréquentes sont également apparues. La prise en charge des maladies cardiovasculaires, de maladies infectieuses et la maladie thromboembolique sont particulièrement concernées.
Asunto(s)
COVID-19 , Epidemias , Tromboembolia Venosa , Humanos , Medicina Interna , SARS-CoV-2RESUMEN
BACKGROUND: The COVID-19 pandemic has led to shortage of intensive care unit (ICU) capacity. We developed a triage strategy including noninvasive respiratory support and admission to the intermediate care unit (IMCU). ICU admission was restricted to patients requiring invasive ventilation. OBJECTIVES: The aim of this study is to describe the characteristics and outcomes of patients admitted to the IMCU. METHOD: Retrospective cohort including consecutive patients admitted between March 28 and April 27, 2020. The primary outcome was the proportion of patients with severe hypoxemic respiratory failure avoiding ICU admission. Secondary outcomes included the rate of emergency intubation, 28-day mortality, and predictors of ICU admission. RESULTS: One hundred fifty-seven patients with COVID-19-associated pneumonia were admitted to the IMCU. Among the 85 patients admitted for worsening respiratory failure, 52/85 (61%) avoided ICU admission. In multivariate analysis, PaO2/FiO2 (OR 0.98; 95% CI: 0.96-0.99) and BMI (OR 0.88; 95% CI: 0.78-0.98) were significantly associated with ICU admission. No death or emergency intubation occurred in the IMCU. CONCLUSIONS: IMCU admission including standardized triage criteria, self-proning, and noninvasive respiratory support prevents ICU admission for a large proportion of patients with COVID-19 hypoxemic respiratory failure. In the context of the COVID-19 pandemic, IMCUs may play an important role in preserving ICU capacity by avoiding ICU admission for patients with worsening respiratory failure and allowing early discharge of ICU patients.
Asunto(s)
COVID-19/terapia , Ventilación no Invasiva , Unidades de Cuidados Respiratorios/estadística & datos numéricos , Insuficiencia Respiratoria/terapia , Anciano , COVID-19/complicaciones , COVID-19/mortalidad , Femenino , Personal de Salud/estadística & datos numéricos , Humanos , Masculino , Persona de Mediana Edad , Insuficiencia Respiratoria/virología , Estudios Retrospectivos , Ausencia por Enfermedad/estadística & datos numéricos , Suiza/epidemiologíaRESUMEN
BACKGROUND: The unfolding of the COVID-19 pandemic during spring 2020 has disrupted medical education worldwide. The University of Geneva decided to shift on-site classwork to online learning; many exams were transformed from summative to formative evaluations and most clinical activities were suspended. We aimed to investigate the perceived impact of those adaptations by the students at the Faculty of Medicine. METHODS: We sent an online self-administered survey to medical students from years 2 to 6 of the University of Geneva, three months after the beginning of the pandemic. The survey explored students' main activities during the first three months of the pandemic, the impact of the crisis on their personal life, on their training and on their professional identity, the level of stress they experienced and which coping strategies they developed. The survey consisted of open-ended and closed questions and was administered in French. RESULTS: A total of 58.8% of students responded (n = 467) and were homogeneously distributed across gender. At the time of the survey, two thirds of the participants were involved in COVID-19-related activities; 72.5% voluntarily participated, mainly fueled by a desire to help and feel useful. Many participants (58.8%) reported a feeling of isolation encountered since the start of the pandemic. Main coping strategies reported were physical activity and increased telecommunications with their loved ones. Most students described a negative impact of the imposed restrictions on their training, reporting decreased motivation and concentration in an unusual or distraction-prone study environment at home and missing interactions with peers and teachers. Students recruited to help at the hospital in the context of increasing staff needs reported a positive impact due to the enriched clinical exposure. Perceived stress levels were manageable across the surveyed population. If changed, the crisis had a largely positive impact on students' professional identity; most highlighted the importance of the health care profession for society and confirmed their career choice. CONCLUSION: Through this comprehensive picture, our study describes the perceived impact of the pandemic on University of Geneva medical students, their training and their professional identity three months after the start of the pandemic. These results allowed us to gain valuable insight that reinforced the relevance of assessing the evolution of the situation in the long run and the importance of developing institutional support tools for medical students throughout their studies.
Asunto(s)
COVID-19 , Estudiantes de Medicina , Adaptación Psicológica , Humanos , Pandemias , SARS-CoV-2RESUMEN
Non-vitamin K antagonist oral anticoagulants (NOAC) present several advantages over vitamin K antagonists, but data with respect to their use in patients with chronic kidney disease is limited. The decision to use oral anticoagulation as well as the choice of the molecule may be difficult in these patients. In patients with moderate kidney disease, NOACs appear to be safe and effective. In advanced kidney disease, they should be used with prudence, after careful assessment of risks and benefits, and at adapted doses. In end stage kidney disease, evidence is weak, suggesting an unfavourable risk benefit ratio. Prescription of oral anticoagulation in these patients has to be individualised in a shared decision making process.
Les anticoagulants oraux directs (ACOD) présentent plusieurs avantages sur les antivitamines K, mais les données concernant leur utilisation en cas d'insuffisance rénale avancée restent rares. Le choix d'anticoaguler et celui de la molécule sont particulièrement ardus chez ces patients. En cas d'insuffisance rénale légère à modérée, les ACOD présentent un profil de sécurité et d'efficacité satisfaisant. En cas d'insuffisance rénale sévère, leur utilisation doit être prudente, avec une évaluation soigneuse des risques et bénéfices, et en adaptant la posologie. Chez les patients avec insuffisance rénale terminale, l'évidence est faible et suggère un rapport bénéfice/risque défavorable pour l'anticoagulation orale. La décision d'anticoaguler et le choix de la molécule nécessiteront une approche individualisée et une décision partagée avec le patient.
Asunto(s)
Anticoagulantes/uso terapéutico , Fibrilación Atrial , Administración Oral , Fibrilación Atrial/tratamiento farmacológico , Coagulación Sanguínea , Fibrinolíticos/uso terapéutico , Humanos , Accidente Cerebrovascular/tratamiento farmacológico , Vitamina K/uso terapéuticoRESUMEN
Climate change and global warming present major clinical challenges. We focus on cardiovascular and renal clinical consequences. The physiological adaptations and physiopathological effects are described, especially in vulnerable populations. The clinical consequences during heat waves, are mainly cardiovascular with stroke, acute ischemic heart disease and sudden death increased by up to 40%. Likewise, episodes of acute renal failure, electrolyte disturbances and kidney stones disease increase. The chronic consequences should not be overlooked, as the risk of heart failure also increases in high ambient temperature regions and there is also some evidence of an increase in chronic kidney disease in tropical zones. Physicians must be aware of these consequences as they will be involved in their management in the future.
Les changements climatiques liés au réchauffement planétaire comportent des enjeux cliniques majeurs. Nous nous concentrerons sur les enjeux cardiovasculaires et rénaux. Les adaptations physiologiques et effets physiopathologiques sont décrits, particulièrement chez des populations vulnérables. Les conséquences cliniques des vagues de chaleur sont en grande majorité cardiovasculaires. Les accidents vasculaires cérébraux, cardiopathies ischémiques aiguës et morts subites sont augmentés jusqu'à 40â %. De même, les épisodes d'insuffisance rénale aiguë, les troubles électrolytiques et les lithiases rénales augmentent. Le risque d'insuffisance cardiaque et le nombre d'insuffisances rénales chroniques augmentent également dans les régions tropicales. Les médecins doivent être conscients de ces conséquences pour lesquelles ils seront impliqués à l'avenir.
Asunto(s)
Cambio Climático , Adaptación Fisiológica , Calentamiento Global , Calor , Humanos , Accidente CerebrovascularRESUMEN
2020: annus horribilis for hospital medicine? The past year, notable because of the current pandemic, has had a profound impact on multiple aspects of medical practice. Just as all medical staff and the general population, hospital internists were put under immense strain in 2020. This year has more than ever reinforced our belief in the importance of keeping a critical and scientific eye on the mass of new studies and data produced every year. The internists of the HUG propose a critical review of selected recent publications that may influence our daily management of patients.
2020 : annus horribilis pour la médecine hospitalière ? L'année écoulée, marquée par la pandémie en cours, a eu un impact majeur sur de multiples aspects de notre pratique. Comme l'ensemble du monde médico-soignant et de la population, les internistes hospitaliers ont été mis à rude épreuve en 2020. Cette année a plus que jamais renforcé notre conviction de l'importance de porter un regard scientifique sur la masse de nouveautés qui surviennent chaque année. Les internistes hospitaliers des HUG vous proposent de partager leur vision critique de publications scientifiques récentes utiles pour notre pratique quotidienne.
Asunto(s)
Medicina Interna , Hospitales , Humanos , MédicosRESUMEN
BACKGROUND: Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, was shown in the DAPA-HF study to reduce the risk of worsening heart failure or death in symptomatic patients with left ejection fraction <40%, irrespective of diabetes. The aim of this study was to evaluate eligibility status for dapagliflozin in non-selected patients hospitalized for acute decompensated heart failure (ADHF), as well as prognostic implications of this status. MATERIALS AND METHODS: Analysis of 815 patients recruited in a prospective cohort of acute heart failure at the University Hospitals of Geneva, consisting of consecutive patients admitted with ADHF. Eligibility for dapagliflozin was determined using criteria described DAPA-HF. RESULTS: Of 815 patients, 220 (27%) were eligible for dapagliflozin treatment. In survival analysis, patients who were eligible for dapagliflozin had better clinical outcomes with respect to all-cause mortality and rehospitalization as compared to those who were not eligible. In multivariate analysis, the hazard ratio for all-cause mortality or readmission in patients eligible for dapagliflozin was 0.82 (95% CI 0.68-0.999, P = .049) as compared to the non-eligible. CONCLUSIONS: Using DAPA-HF criteria, only 27% of non-selected patients admitted for ADHF are theoretically eligible for dapagliflozin. This eligibility for dapagliflozin is associated with better outcomes. Further evaluation of the benefits of dapagliflozin in selected HF patients may be of interest. This may have implications for selection criteria in future randomized effectiveness studies.
Asunto(s)
Compuestos de Bencidrilo/uso terapéutico , Determinación de la Elegibilidad , Glucósidos/uso terapéutico , Insuficiencia Cardíaca/terapia , Mortalidad , Readmisión del Paciente/estadística & datos numéricos , Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico , Enfermedad Aguda , Anciano , Anciano de 80 o más Años , Causas de Muerte , Estudios de Cohortes , Femenino , Insuficiencia Cardíaca/metabolismo , Insuficiencia Cardíaca/fisiopatología , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Pronóstico , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Ensayos Clínicos Controlados Aleatorios como Asunto , Volumen SistólicoRESUMEN
BACKGROUND: Optimal clinical care of patients with chronic kidney disease (CKD) requires collaboration between primary care physicians (PCPs) and nephrologists. We undertook a randomised trial to determine the impact of superimposed nephrologist care compared to guidelines-directed management by PCPs in CKD patients after hospital discharge. METHODS: Stage 3b-4 CKD patients were enrolled during a hospitalization and randomised in two arms: Co-management by PCPs and nephrologists (interventional arm) versus management by PCPs with written instructions and consultations by nephrologists on demand (standard care). Our primary outcome was death or rehospitalisation within the 2 years post-randomisation. Secondary outcomes were: urgent renal replacement therapy (RRT), decline of renal function and decrease of quality of life at 2 years. RESULTS: From November 2009 to the end of June 2013, we randomised 242 patients. Mean follow-up was 51 + 20 months. Survival without rehospitalisation, GFR decline and elective dialysis initiation did not differ between the two arms. Quality of life was also similar in both groups. Compared to randomised patients, those who either declined to participate in the study or were previously known by nephrologists had a worse survival. CONCLUSION: These results do not demonstrate a benefit of a regular renal care compared to guided PCPs care in terms of survival or dialysis initiation in CKD patients. Increased awareness of renal disease management among PCPs may be as effective as a co-management by PCPs and nephrologists in order to improve the prognosis of moderate-to-severe CKD. TRIAL REGISTRATION: This study was registered on June 29, 2009 in clinicaltrials.gov (NCT00929760) and adheres to CONSORT 2010 guidelines.
Asunto(s)
Comunicación Interdisciplinaria , Nefrología/métodos , Manejo de Atención al Paciente , Atención Primaria de Salud/métodos , Derivación y Consulta/organización & administración , Insuficiencia Renal Crónica , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Evaluación de Procesos y Resultados en Atención de Salud , Gravedad del Paciente , Manejo de Atención al Paciente/métodos , Manejo de Atención al Paciente/organización & administración , Médicos de Atención Primaria , Guías de Práctica Clínica como Asunto , Pronóstico , Insuficiencia Renal Crónica/diagnóstico , Insuficiencia Renal Crónica/terapia , Nivel de Atención/organización & administraciónRESUMEN
Cirrhosis results from chronic liver disease and is associated with a high mortality. The most frequent causes for chronic liver disease include alcoholic liver disease, non-alcoholic fatty liver disease and viral hepatitis B and C. Bacterial infections often complicate decompensated cirrhosis. It is estimated that up to 35% of patients with decompensated cirrhosis have an infection at admission or during hospital stay. There are considerable consequences to these bacterial infections. Whilst evidence supports the use of prophylactic antibiotics, the emergence of multi-resistant bacteria is changing the spectrum of antibiotics that have to be used.
La cirrhose, résultat d'une maladie chronique du foie, est grevée d'une mortalité élevée. Les causes les plus fréquentes sont les hépatopathies alcoolique et dysmétabolique ainsi que les hépatites virales B et C. Les infections bactériennes sont une cause fréquente de complication de la décompensation cirrhotique. Il est estimé que 25 à 35â % des patients en décompensation cirrhotique présentent une infection à leur admission ou durant le séjour hospitalier. Les conséquences de l'infection bactérienne chez un patient cirrhotique sont considérables. L'évidence soutient l'utilisation d'une antibiothérapie prophylactique, mais la présence de plus en plus fréquente de germes avec des profils de résistance étendus pousse à recourir aux antibiotiques à spectre large.
Asunto(s)
Infecciones Bacterianas , Cirrosis Hepática , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Infecciones Bacterianas/complicaciones , Infecciones Bacterianas/tratamiento farmacológico , Farmacorresistencia Microbiana/efectos de los fármacos , Humanos , Cirrosis Hepática/complicaciones , Hepatopatías Alcohólicas/complicaciones , Enfermedad del Hígado Graso no Alcohólico/complicacionesRESUMEN
Whilst the pathophysiology underlying the diverse thrombotic microangiopathy syndromes is better understood, management of these entities and of the various therapeutic options currently available remains challenging. Early identification of these syndromes is essential to improving prognosis. In the absence of treatment, mortality is high, including in the first days following diagnosis. We present a summary of the diagnostic strategy and therapeutic management of thrombotic microangiopathy in adults.
Alors que la physiopathologie de la microangiopathie thrombotique est de mieux en mieux comprise, la gestion de cette entité en aigu et les différentes options thérapeutiques à disposition restent moins claires. Son identification précoce est indispensable pour permettre une amélioration du pronostic. En l'absence de traitement, le taux de mortalité est très élevé, et ce dans les premiers jours qui suivent le diagnostic. Cet article a pour objectif de permettre une synthèse des stratégies diagnostique et thérapeutique à adopter devant une suspicion de microangiopathie thrombotique chez l'adulte.
Asunto(s)
Microangiopatías Trombóticas , Humanos , Pronóstico , Síndrome , Microangiopatías Trombóticas/diagnóstico , Microangiopatías Trombóticas/terapiaRESUMEN
This selective overview of articles describes new concepts, therapeutic measures and pharmacological agents that may modify current practice in internal medicine. Implications for management of cardiovascular disease, such as heart failure, diabetes and infectious diseases figure prominently.
À travers quelques articles et études choisis, cette revue sélective décrit de nouveaux concepts, mesures thérapeutiques et agents pharmacologiques qui peuvent modifier les pratiques courantes en médecine interne. Des notions concernant la gestion de maladies cardiovasculaires, telles que l'insuffisance cardiaque, le diabète et les maladies infectieuses, y figurent au premier plan.
Asunto(s)
Enfermedades Cardiovasculares , Insuficiencia Cardíaca , Medicina Interna , Enfermedades Cardiovasculares/terapia , Insuficiencia Cardíaca/terapia , Humanos , Medicina Interna/tendenciasRESUMEN
BACKGROUND: Minimal lipoprotein(a) [Lp(a)] target values are advocated for high-risk cardiovascular patients. We investigated the prognostic value of Lp(a) in the acute setting of patients with acute coronary syndromes (ACS). MATERIALS AND METHODS: Plasma levels of Lp(a) were collected at time of angiography from 1711 patients hospitalized for ACS in a multicentre Swiss prospective cohort. Associations between elevated Lp(a) ≥30 mg/dL (cut-off corresponding to the 75th percentile of the assay) or Lp(a) tertiles at baseline, and major adverse cardiovascular events (MACE) at 1 year, defined as a composite of cardiac death, myocardial infarction or stroke, were assessed using hazard ratios (HR) and 95% confidence intervals (CI) adjusting for traditional cardiovascular risk factors (age, sex, smoking, diabetes, hypertension, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C] and triglycerides. RESULTS: Lp(a) levels range between 2.5 and 132 mg/dL with a median value of 6 mg/dL and a mean value of 14.2 mg/dL. A total of 276 patients (23.0%) had Lp(a) plasma levels ≥30 mg/dL. Patients with elevated Lp(a) were more likely to be of female gender and to have higher levels of total cholesterol, LDL-C, HDL-C and triglycerides. Higher Lp(a) was associated with failure to reach the LDL-C target <1.8 mmol/L at 1 year (HR 1.71, 95% CI 1.13-2.58, P = 0.01). No association was found between elevated Lp(a) and MACE at 1 year (HR 1.05, 95% CI 0.64-1.73), nor for Lp(a) tertiles (HR 0.82, 95% CI 0.52-1.28, P > 0.20) or standardized continuous variables (0.98, 95% CI 0.82-1.19 for each increase of standard deviation). CONCLUSIONS: Our real-world data suggest high Lp(a) levels at time of angiography are not predictive for cardiovascular outcomes in patients otherwise medically well controlled, but might be useful to identify patients who would not be on LDL-C targets 1 year after ACS.
Asunto(s)
Síndrome Coronario Agudo/sangre , Lipoproteína(a)/metabolismo , Biomarcadores/metabolismo , HDL-Colesterol/metabolismo , LDL-Colesterol/metabolismo , Muerte Súbita Cardíaca/etiología , Femenino , Humanos , Hiperlipoproteinemia Tipo II , Masculino , Persona de Mediana Edad , Infarto del Miocardio/etiología , Pronóstico , Estudios Prospectivos , Accidente Cerebrovascular/etiología , Triglicéridos/metabolismoRESUMEN
Upper gastrointestinal bleeding is an urgent entity associated with a high mortality of about 10â %. Its urgent management includes medical interventions such as volume repletion, blood transfusions, the use of proton pump inhibitors, as well as upper gastrointestinal endoscopy. Whilst the benefit of esophago-gastro-duodenoscopy is clearly demonstrated, the ideal timing for this intervention is less well established. Initial management and pharmacological interventions are important and well-integrated into protocols.
L'hémorragie digestive haute est une entité urgente bien connue du gastroentérologue avec une mortalité élevée avoisinant les 10â %. Sa prise en charge inclut des moyens médicaux, comme la réanimation liquidienne, les transfusions sanguines ou les inhibiteurs de la pompe à protons, et l'endoscopie digestive. Alors que le bénéfice de l'Åsophago-gastro-duodénoscopie a depuis longtemps été démontré, le délai idéal pour sa réalisation reste peu clair. La prise en charge initiale et les interventions médicamenteuses sont également importantes et intégrées dans des protocoles.
Asunto(s)
Endoscopía Gastrointestinal , Hemorragia Gastrointestinal/diagnóstico , Hemorragia Gastrointestinal/cirugía , Transfusión Sanguínea , Duodenoscopía , Esofagoscopía , Gastroscopía , Humanos , Inhibidores de la Bomba de Protones/uso terapéuticoRESUMEN
Confronted with increasingly complex and interdependent medical situations, targeted clinical answers and recommendations are -increasingly the result of a comprehensive appraisal of existing -evidence. In addition, public health and economic stakes have to be considered and integrated into the decision process, diagnosis and management of numerous clinical entities. This selective overview covers some of these entities and demonstrate the expanding overlap between inpatient and outpatient practice.
Face à des problématiques médicales de plus en plus complexes et interdépendantes, des réponses et recommandations ciblées sont aujourd'hui proposées, basées sur une revue compréhensive de la littérature. Des enjeux de santé publique et d'économie de la santé viennent s'ajouter au processus décisionnel, diagnostique, et de prise en charge dans de nombreuses pathologies. Cette revue sélective traite de certains de ces sujets et démontre l'accroissement du chevauchement entre médecines hospitalière et ambulatoire.